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ABSTRACT
Purpose The aim of current study was to develop a dried
inactivated polio vaccine (IPV) formulation with minimal loss dur-
ing the drying process and improved stability when compared
with the conventional liquid IPV.
Methods Extensive excipient screening was combined with the
use of a Design of Experiment (DoE) approach in order to achieve
optimal results with high probability.
Results Although it was shown earlier that the lyophilization of a
trivalent IPV while conserving its antigenicity is challenging, we were
able to develop a formulation that showed minimal loss of potency
during drying and subsequent storage at higher temperatures.
Conclusion This study showed the potential of a highly stable
and safe lyophilized polio vaccine, which might be used in devel-
oping countries without the need of a cold-chain.
KEY WORDS design of experiments . formulation . inactivated
polio vaccine . lyophilization
ABBREVIATIONS
(s)IPV (Sabin) inactivated polio vaccine
cVDPV Circulating vaccine-derived poliovirus
DoE Design of experiments
DU D-antigen unit
MSG Monosodium glutamate
OPV Oral polio vaccine
PLS Partial least square
RMC Residual moisture content
VAPP Vaccine-associated paralytic poliomyelitis
INTRODUCTION
Poliomyelitis is a highly infectious disease, which mainly af-
fects young children. The disease, caused by any one of three
serotypes of poliovirus (type 1, type 2 or type 3) has no specific
treatment, but can be prevented through vaccination.
Currently, the live attenuated oral poliomyelitis vaccine
(Sabin OPV) is the vaccine of choice to prevent polio out-
breaks and stop transmission of wild polioviruses, especially in
the remaining endemic countries. However, a major concern
is the ability of OPV to revert to a form that can cause
paralysis, so-called vaccine-associated paralytic poliomyelitis
(VAPP). Permanent use of OPV would continue to generate
circulating vaccine-derived polioviruses (cVDPVs) that will
inevitably lead to new outbreaks (1). Therefore, the new
endgame strategy of the Global Polio Eradication Initiative
(GPEI) includes the introduction of an inactivated polio vac-
cine (IPV) into all routine immunization programs followed by
phased withdrawal of OPV (2). In most of the high-income
countries, IPV based on Salk strains is already the present
preferred way to eliminate the risk of VAPP and cVDPVs.
To achieve global polio eradication, an (improved) IPV
must be efficacious, inexpensive, safe to manufacture, and easy
to administer (3). The feasibility of current IPV in developing
countries is limited, because IPV is more expensive than OPV
and is administered through injections only. In order to extent
the availability of IPV, theWorld HealthOrganization (WHO)
and the Institute for Translational Vaccinology (Intravacc) in
the Netherlands have developed a non-commercial IPV for
technology transfer to developing countries (4). Because the
containment of the wild-type Salk poliovirus during production
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might be an issue, especially in developing countries, the new
vaccine will be based on the traditional Sabin OPV strains
(sIPV). For reduction in costs, Intravacc is developing sIPV
formulations that show dose sparing by using an adjuvant (5)
and/or other immunization routes (6,7).
Vaccine delivery encompasses both administration of the
vaccine formulation to specific sites and delivery of the antigen
to and activation of relevant cells of the immune system (8).
Since alternative delivery methods and improved vaccine
formulations have the potential to make vaccine delivery
easier and safer (9,10), several alternative vaccine delivery
methods are currently being developed. However, the focus
in vaccine development has been on optimization of the
immunological properties, while stability issues are minimally
addressed. Most vaccines, IPV included, are insufficiently
stable to allow them to be purified, transported and stored
at unrefrigerated conditions (11,12).
One way to improve the storage stability of (s)IPVmight be
conversion into the dry state as is known to improve the
stability of biopharmaceuticals (13). An increased shelf life is
not only of use for the final product for use within 3 months to
2 years, but also for stockpiling (1–10 or more years of stor-
age). Particularly after polio eradication, a stockpile of polio
vaccines is required to anticipate the potential risk of new
polio outbreaks caused by circulating VDPV (even after
OPV cessation) (14,15) or bioterrorism attacks. In order to
achieve an optimal vaccine stockpile, various issues need to be
considered. The shelf life is paramount, because a delayed
expiration time will reduce the stockpile costs (16). Moreover,
storage of dried materials at ambient temperature, including
concomitant costs (e.g., reformulation costs), is cost effective
compared with storage options at low temperatures. In addi-
tion, the ability to develop solid antigen formulations is crucial
for new vaccine delivery routes including dermal delivery by
coated or dissolving microneedles, parenteral delivery by
powders or dissolvable needles, and pulmonary delivery of
powders (8). Technologies for producing dried biologicals
include vacuum drying, air-drying, coating, spray
(freeze-)drying and foam-drying (17–19). One of the oldest
and commonly used techniques is freeze-drying, also called
lyophilization. However, during the lyophilization process the
proteinaceous vaccine is subjected to freezing and drying
stress by which its activity can be lost. Therefore, cryoprotec-
tive and lyoprotective agents are required. Many compounds,
such as sugars, polymers, amino acids and surfactants, have
been shown to improve the stability of biopharmaceuticals
during lyophilization and subsequent storage (20).
The aim of current study is to design IPV in the dry state
with maintenance of the potency. A potency indicating param-
eter is D-antigenicity, which can be determined in ELISA using
specific antibodies as stated in the European Pharmacopeia.
Lyophilization of polio vaccines has been shown to be chal-
lenging since earlier studies failed to obtain a stable product
with preservation of all three serotypes (21–23). We describe
the development of an IPV formulation by selecting excipients
that i) minimize potency loss upon drying and subsequent
reconstitution, and ii) increase the stability of IPV at elevated
temperatures. Extensive excipient screening was combined
with the use of a Design of Experiment (DoE) approach in
order to achieve optimal results with high probability.
MATERIALS AND METHODS
Materials
Trivalent IPV, containing the inactivated Mahoney strain for
type 1, MEF for type 2 and Saukett for type 3, was obtained
from the process development department of Intravacc
(Bilthoven, The Netherlands). The ten times concentrated triva-
lent bulk used in this study was determined at a nominal con-
centration of 400-80-320 DU/ml by ELISA as described (24).
The excipients sucrose, D-sorbitol, D-trehalose dihydrate,
mannitol, L-glutamic monosodium salt monohydrate (MSG),
glycine, myo-inositol, magnesiumchloride hexahydrate, lithi-
um chloride and ovalbumin were all purchased from Sigma
(St. Louis,MO). Peptone (vegetable) and dextran (6 kDa, from
Leuconostoc ssp.) were from Fluka (Buchs, Switzerland) and
sodium chloride was from Merck (Darmstadt, Germany). To
prepare 10 mM McIlvaine buffer, 10 mM citric acid (Sigma-
Aldrich, St. Louis, MO) was added to 10 mM disodium
hydrogen phosphate dehydrate (Na2HPO4) (Fluka, Buchs,
Switzerland) in a ratio of 1:6 resulting in a pH-value of 7.0.
All excipients used were of reagent quality or higher grade.
Methods
Dialysis
Unless otherwise indicated, the trivalent IPV bulk material
was dialyzed against 10 mMMcIlvaine buffer (pH 7.0) using a
10 kDa molecular weight cut-off, low-binding regenerated
cellulose membrane dialysis cassette (Slide-A-Lyzer®, Pierce,
Thermo Scientific, Rockford, IL) to replace the buffer com-
ponents of the IPV bulk (M199 medium).
Formulations
All excipients were dissolved in McIlvaine buffer at a double
concentration of the indicated end concentration. The dialyzed
IPVwasmixed 1:1 by volumewith the formulation to be tested.
Subsequently, 2 ml neutral glass injection vials (Müller +
Müller, Holzminden, Germany) were filled with 0.2 ml of the
IPV-excipient mixtures and half-closed with 13 mm pre-dried
(overnight at 90°C) rubber stoppers (type V9250 from Helvoet
Pharma, Alken, Belgium).
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Drying Processes
The filled (0.2ml/vial) and half-stopped vials were loaded into
a pilot freeze dryer (freeze-drying unit sublimator 2-3-3,
Zirbus) at a shelf temperature of −50°C, or at a shelf of 4°C
and subsequently frozen to −50°C by reducing the shelf
temperature at a rate of 1°C/min. These different processes
will be denoted as fast and slow freezing, respectively. The
vials were kept at a temperature of −50°C for 2 h. For the
primary drying phase, the shelf temperature was increased at
a rate of 0.2°C/h to −45°C (while decreasing the chamber
pressure to 0.045 mbar) followed by drying for 3 h. The
secondary drying phase was performed by further increasing
the shelf temperature at 0.02°C/min to 25°C while decreas-
ing the chamber pressure to 0.01 mbar, followed by 24 h
drying at 25°C. At the end of the cycle, the vials were closed
under vacuum, sealed with alu-caps and kept at 4°C until
analysis.
In literature, different vacuum drying processes are de-
scribed (25–27). The vacuum drying process used in current
study was slightly adapted, due to the characteristics of IPV.
Briefly, the vials were loaded at shelves of 15°C and kept at
that temperature for 10 min. The chamber pressure was
reduced to 1 mbar in different ramping steps of 15 min and
starting at a 25 mbar chamber pressure. The temperature was
decreased to −10°C for 1 h at 0.05 mbar and for 1 h at
0.03 mbar so that freezing of the formulations was prevented
since product temperature was kept above the ice-nucleation
temperature of the formulations. Subsequently, shelf temper-
ature was increased at 0.05°C/min to 30°C. At the end of the
cycle, the vials were closed under vacuum, sealed with alu-
caps and kept at 4°C until analysis.
Design of Experiments (DoE)
The Design of Experiments models for D-antigen recoveries
measured by ELISA were evaluated in Modde 9.1 software
(Umetrics AB, Umea, Sweden) to establish the stability pro-
files of the lyophilized IPV. In a first pilot experiment, the
effect of common used stabilizers, i.e., sucrose (0–20% w/v),
trehalose (0–20% w/v), mannitol (0–10% w/v), dextran (0–
10% w/v) and NaCl (0–63 mM), was determined using a D-
optimal design containing of 22 different formulations and
three replicates of the center point (supplemental data,
Table SI). For the screening of some excipients, a full factorial
DoE was performed around sorbitol, MgCl2, monosodium
glutamate (MSG) and mannitol, all within the concentration
range from 0 to 10% w/v. In this full factorial design 24
formulations were tested and three replicates of the center
point (Table II). For the optimization experiment a central
composite circumscribed (CCC) design was used around sor-
bitol (8 to 12% w/v), MgCl2 (5 to 12% w/v) and MSG (5 to
12% w/v). The CCC design consisted of eight corner
experiments, six axial experiments and three replicated center
points (Table III). The models were fitted using partial least
squares (PLS) regression and subsequent optimized by deleting
non-significant terms leading to a model with the best model
performance parameters, i.e., goodness of fit (R2), goodness of
prediction (Q2), model validity and reproducibility.
D-antigen ELISA
A sandwich enzyme-linked immunosorbent assay (ELISA)
was used to quantify D-antigen units (DU) of the lyophilized
polio vaccine formulations as described by Ten Have et al.
(2012) (28). Briefly, microtiter plates were coated with
serotype-specific bovine anti-polio serum (Bilthoven
Biologicals, Bilthoven, The Netherlands). After washing dilu-
tions of IPV-formulations were added (in duplicate). After a
30 min incubation at 37°C under gentle shaking, plates were
washed and a mixture of serotype-specific anti-poliovirus
monoclonal antibody (mab 3-4-E4 (type 1), 3-14-4 (type 2),
1-12-9 (type 3); all from Intravacc, Bilthoven, The
Netherlands) and HRP-labeled anti-mouse IgG (GE
Healthcare, Buckinghamshire, UK) was added and incubated
for 30 min at 37°C while shaking. Subsequently, plates were
washed followed by addition of ELISA HighLight signal re-
agent (ZomerBloemen BV, Zeist, The Netherlands).
Chemiluminescence was measured for 10–15 min by using a
luminometer (Berthold Centro LB960). The signal at maxi-
mum intensity was used to calculate D-antigen content rela-
tive to the reference standard. Unless otherwise indicated, DU
recovery values were shown as normalized values for liquid
formulations prior to lyophilization.
Dynamic Light Scattering (DLS)
Particle size measurements were performed using a Zetasizer
Nano-ZS system (Malvern Instruments, Malvern, UK). DLS
measurements were done in triplicate with 0.5 ml liquid
(undialyzed) IPV bulk at an operating temperature of 25ºC.
Homogeneity of the size distribution was reflected in the
polydispersity index (PdI), which ranges between 0.0 (fully
homogeneous size distribution) and 1.0 (random size
distribution).
Moisture Content Analysis
The water content was determined using a Karl Fischer
coulometric titrimeter (Model CA-06 Moisture meter,
Mitsubishi). The samples were weighted, subsequently
reconstituted in the Karl-Fischer reagent, Hydrana
Coulomat A (Fluka, Buchs, Switzerland), and injected into
the titration vessel. Each vial was measured in triplicate. The
empty vials were weighted and the water content was calcu-
lated based on the water content measured by the titrimeter,
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the weight of the lyophilized product in the vial, the reconsti-
tution volume of the reagent, titration volume and the water
content of the blank titration.
Differential Scanning Calorimetry (DSC)
The thermodynamic behavior of the formulations was deter-
mined by differential scanning calorimetry (DSC). Aluminum
DSC pans were filled with the liquid formulations and sub-
jected to a controlled temperature program in a differential
scanning calorimeter (DSC Q100, TA Instruments). The
samples were cooled to −70°C at a rate of 10°C/min, kept
isothermal for 2 min, and subsequent heated to 20°C at a
heating rate of 10°C/min. The sample chamber was purged
with nitrogen gas (50 ml/min). The glass transition tempera-
tures (Tg’) were determined as the midpoint of the disconti-
nuities in the heat flow curves using thermal analysis software
(Universal Analysis 2000, TA Instruments).
RESULTS & DISCUSSION
Common Lyoprotectants
The first design of experiment approach was based on the
most commonly used lyoprotectants, i.e., sucrose, trehalose
and mannitol, in combination with dextran, with and without
NaCl (Table SI, supplemental data). These excipients are
known to provide physical and biochemical stabilization as
well as appropriate structural properties to the cake structure,
during and after lyophilization (29–32).
A partial least squares (PLS) regression model was fitted
and optimized per serotype, which resulted in valid models to
predict the DU recoveries directly after lyophilization accord-
ing to the model performance parameters. For serotype 1, 2
and 3, the Q2 values were, respectively, 0.650, 0.592 and
0.671, while the R2 values were 0.905, 0.873 and 0.929.
The effects of the different stabilizers, after optimization
a
b
Fig. 1 Stabilizing potential of the excipients sucrose (SUC), trehalose (TRE), mannitol (MAN), dextran (DEX) and NaCl on DU recovery directly after
lyophilization. Main and interaction effects that contribute (per serotype) to the best model, according to the model performance parameters (Q2=0.650, R2=
0.905 (type 1); Q2=0.592, R2=0.873 (type 2); Q2=0.671, R2=0.929 (type 3)), are depicted in coefficient plots (a). Surface response plots of the DU
recovery for each serotype based on formulations containing sucrose and trehalose in combination with 10% mannitol (without dextran or NaCl) (b).
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(excluding non-significant parameters) on the DU recovery
after lyophilization are presented in Fig. 1a.
Without the addition of stabilizers, DU recoveries of type
1, 2 and 3 after lyophilization were 9, 11 and 2%, respectively
(Table SI, supplemental data). Both sucrose and mannitol are
able to stabilize all serotypes to a certain extent during the
lyophilization process (Fig. 1a). Dextran has a negative effect
on type 1 and 3 during the lyophilization process, whereas the
addition of NaCl has no significant effect on the DU recovery,
independent of serotype (Fig. 1a). Best results, with recoveries
of approximately 55%, 85% and 50% for serotype 1, 2 and 3
respectively, were obtained with formulations containing su-
crose and/or trehalose in combination with mannitol
(Fig. 1b). Among the three serotypes, type 2 was the least
affected during lyophilization, resulting in a maximum recov-
ery of 85% after lyophilization. This serotype is known to be
the most stable at higher temperatures (33).
This first experiment illustrates the complexity of lyophiliz-
ing a trivalent polio vaccine retaining its antigenicity and
displays that each serotype may behave different within the
same formulations. It has been reported earlier that lyophili-
zation of polio vaccines is challenging. For example, Nagel
et al. revealed that with the excipients sorbitol and peptone
relative potencies of 70% for type 1 and 50% for type 2 could
be obtained after lyophilization of IPV, while all activity of
type 3 was destroyed (22). In addition, Pollard et al. exhibited
that lyophilization of the wild type poliovirus resulted in
almost complete inactivation (34), although it was not deter-
mined whether D-antigenicity was also negatively affected.
Table I Formulations Tested in an Excipient Screening Experiment (S). DU Recoveries were Determined Directly After Lyophilization
Sugars Polyols Amino acids Proteins Other DU recovery (%)
T1 T2 T3
S0 – – – – – 12 17 2









7% ovalbumin 10 mM EDTA 66 81 77








– – 3% ovalbumin – 27 58 12





















0.01% Tween80 38 82 43
S9 5% sucrose 3% lysine
3% alanine
3% Ca-lactobionate 36 36 24
S10 5% sucrose 3% lysine
3% alanine
3% rec. gelatin 45 72 46
S11a – 5% sorbitol – 5% peptone 2% MgCl2 80 79 75
S12a – 5% sorbitol – 5% peptone 1% LiCl 86 100 87
S13 5% sucrose
5% trehalose
– – 5% peptone – 29 62 26



























type 1 type 2 type 3
negative control 10% sucrose 10% trehalose
Fig. 2 DU recovery of dried IPVusing different drying methods, i.e., vacuum
drying (V) or lyophilization with low (FD-low) or high freezing rate (FD-high).
Common used stabilizing sugars sucrose (10% w/v) and trehalose (10% w/v)
were compared with the formulation without additives (negative control).
Mean values (n=3) and SD are shown.
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Drying Methods
Literature indicates that vacuum drying, a drying process
without a freezing step, can be used to stabilize IPV (35).
With the use of disaccharides sucrose and trehalose as stabi-
lizing agents, it is feasible to obtain a dried (or highly viscous)
polio vaccine by vacuum drying without affecting its potency.
As a result, we decided to investigate the impact of different
drying processes on the integrity of IPV. Trehalose and su-
crose based IPV formulations were vacuum dried and com-
pared with the same formulations that underwent different
lyophilization processes. One lyophilization process starting
with a slow freezing step (cooling of shelves from 4°C to
−50°C, at 1°C/min) and one with a fast freezing step (shelves
pre-cooled to −50°C as has been used in the pilot experi-
ment). The conventional trivalent IPV formulation, without
any additives, showed recoveries <15% for all serotypes after
vacuum drying or lyophilization (Fig. 2). The vacuum drying
process yielded highly viscous IPV formulations with a water
content of respectively 9% or 12% for the formulations con-
taining sucrose or trehalose, whereas lyophilization yielded
formulations with a water content of <1%. While more than
55% of the antigen is intact after vacuum drying of IPV
containing 10% trehalose, both lyophilization processes re-
sulted in almost complete loss of D-antigenicity. These results
depict both one of the main disadvantages of vacuum drying
as well as the opportunity to dry without freezing stresses. The
high moisture content is caused by the relatively low specific
surface area during vacuum drying, which results in an ex-
tremely slow secondary drying when compared to lyophiliza-
tion. As a result, the risk of sugar crystallization and/or phase
separation in the rubbery state exists (13).
The poor recoveries depicted in Fig. 2 suggest that neither
trehalose nor sucrose alone was able to protect IPV against
both the freezing and drying stresses during lyophilization.
Although the different freezing rates of the lyophilization
processes did not show significant differences in D-
antigenicity, particle size measurements after freeze thawing
revealed differences in IPV particle size that were dependent
on freezing rate. Slowly frozen IPV had a size of 44.7±2.1 nm
with a PdI of 0.485±0.062, whereas fast frozen IPV remains
at a particle size of 38.7±1.1 nm with a PdI of 0.166±0.009
(similar to IPV bulk prior to freeze thawing). Thus, IPV
appeared to be most resistant to freeze thawing when a fast
freezing rate was applied, which induced less aggregation than
slow freezing. For that reason, a fast freezing step was selected
for optimization of the IPV formulation for lyophilization.
Extensive Excipient Screening
In order to obtain an IPV formulation that is suitable for
lyophilization we performed a more extensive excipient
screening. The selection of excipients for the screening
(Table I) was based on findings from literature (20,22,36–40)
and earlier unpublished data.
In general, the formulations containing sorbitol showed
high recoveries directly after lyophilization. Especially formu-
lations containing sorbitol, mannitol and monosodium gluta-
mate (MSG) stabilized the IPV during the process of freezing
and subsequent dehydration with DU recoveries of >65% for
all serotypes (Table I; S1–S3, S6). Another notable formula-
tion is the combination of sorbitol, peptone and the salts LiCl
or MgCl2 (Table I; S11 and S12) indicating that this combi-
nation of excipients is able to protect the IPV during lyophi-
lization. The best formulations, which showed DU recoveries






































































type 1 type 2 type 3
d
Fig. 3 DU recoveries of the best formulations from the screening experi-
ment based on recoveries directly after lyophilization (>60% for all sero-
types). Panel (a) shows the DU recoveries directly after lyophilization. Panel
(b, c and d) show the recoveries after incubation for 1 week at 45°C, 2 weeks
at 37°C, and 4 weeks at room temperature, respectively. The formulations
are described in Table I.
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selected and subsequently tested for stability (Fig. 3). In gen-
eral, the tested formulations so far showed disastrous recover-
ies after incubation at higher temperatures (Fig. 3b–c) and
even after incubation for a month at ambient temperature, a
large drop in antigenicity was observed (Fig. 3d).
The appropriate performance of sorbitol combined with
mannitol and MSG indicates that the presence of polyols in
combination withMSG stabilizes the IPV during lyophilization
in a similar way as the disaccharides sucrose and/or trehalose
(combined with mannitol) did as shown in the pilot study. In
earlier lyophilization studies, sorbitol was used as excipient in
combination with peptone (22), which showed again to be a
valuable combination in this experiment, whether or not in the
presence of a salt like MgCl2 or LiCl. Peptone-containing
lyophilized IPV formulations, however, showed limited storage
stability at elevated temperatures (Fig. 3b–c). Furthermore,
peptone is poorly defined and heterogeneous in composition;
therefore, it was chosen to exclude peptone further in the
formulation design. MgCl2’s stabilizing potential has been de-
scribed for fluid oral polio vaccine. As a result, a number of
manufacturers use MgCl2 to stabilize their OPV (39). Thus,
MgCl2 could also be a critical additive in a dried IPV
formulation.
Design of Experiments—Full Factorial Design
Based on the results of our study so far, we selected the most
promising excipients to screen them further using a DoE
approach and get more insight in the IPV stabilizing potential
of these additives. Therefore, a full factorial design was per-
formed around the excipients sorbitol, MSG, MgCl2 and
mannitol (all in the concentration range of 0–10% w/v)
(Table II). The mixture of sorbitol, mannitol and MSG has
























D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19







type 1 type 2 type 3
b
Fig. 4 The stabilizing effect of
sorbitol, MgCl2, MSG and mannitol
was investigated in a screening
experiment using a DOE approach.
Mean DU recoveries and standard
deviations (n=3) directly after
lyophilization (a) and after
incubation for 1 week at 45°C (b)
are shown.
Table II Excipients Sorbitol, MgCl2, MSG and Mannitol (all 0–10% w/v)
Examined in a Full Factorial Design (D). Glass Transition Temperature (Tg’) of
the Liquid Formulation Before Lyophilization and Residual Moisture Content
(RMC) of the Dried Cake were Determined
Sorbitol MgCl2 MSG Mannitol Tg’ RMC
(°C) (%)
D1 – – – – n.d. 0.2
D2 10% – – – −43.4 2.4
D3 – 10% – – n.d. 45.9
D4 10% 10% – – n.d. 20.6
D5 – – 10% – −47.0 7.4
D6 10% – 10% – −41.2 1.8
D7 – 10% 10% – −58.6 4.0
D8 10% 10% 10% – −49.6 7.6
D9 – – – 10% −34.6 1.1
D10 10% – – 10% −40.5 0.3
D11 – 10% – 10% n.d. 16.1
D12 10% 10% – 10% −51.6 17.1
D13 – – 10% 10% −41.0 2.8
D14 10% – 10% 10% −39.7 2.3
D15 – 10% 10% 10% −51.2 8.2
D16 10% 10% 10% 10% −48.2 9.7
D17 5% 5% 5% 5% −48.1 5.8
D18 5% 5% 5% 5% −47.7 17.7
D19 5% 5% 5% 5% −47.7 9.7
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during the lyophilization process. In addition, mannitol was
selected as a common bulking agent due to its excellent cake-
forming property and the option to apply annealing when
needed (41,42). As mentioned above, MgCl2 is already a
proven stabilizer for OPV and therefore we examined its
contribution in a dried IPV formulation as well.
Figure 4a shows that sorbitol seemed to be an important
excipient for the stabilization of both type 1 and 2 during
lyophilization with recoveries up to 89% (Formulation D2 and
D8). DU recoveries after one week accelerated stability testing
clearly illustrate the benefit of sorbitol, as well as MgCl2 and
MSG in the formulation (Fig. 4a, formulation D8). Regression
models (R2>0.65 and Q2>0.5) of these data confirm the
findings that are described above. The stabilizing effects of
the excipients on DU recovery directly after lyophilization are
depicted per serotype in coefficient plots after model optimi-
zation (Fig. 5a). For all serotypes, there is a main effect of
sorbitol, whereas MSG showed to be significant beneficial for
the DU recovery of type 1 and 3. However, sorbitol showed
an interaction with mannitol that negatively affected IPV
recovery after lyophilization, implying that the addition of
mannitol to the IPV formulation for lyophilization is not
desired. Accelerated stability testing revealed that MgCl2
and MSG are important stabilizers for all serotypes, indicated
by significant main effects and interaction between these ex-
cipients. This means that the addition of MgCl2 or MSG
(10% w/v) results in an increase of 7–13% in DU recovery,
while the combination of these excipients would boost the
D-antigenicity with 6–10%. The inclusion of MgCl2 to the
IPV formulation increases the residual water content
(Table II) after lyophilization significantly. This excipient is
also responsible for reducing the glass transition temperatures
(Tg’) of the formulation before drying. The sorbitol and MSG
interaction factor is able to increase the Tg’ significantly (data
a
b
Fig. 5 Stabilizing potential of the excipients sorbitol (SOR), MgCl2, monosodium glutamate (MSG) and mannitol (MAN) on the DU recovery directly after
lyophilization. Main and interaction effects that contribute (per serotype) to the best fitted model, according to their model performance parameters (Q2=0.685,
R2=0.923 (type 1); Q2=0.577, R2=0.877 (type 2); Q2=0.575, R2=0.824 (type 3)) are shown in coefficient plots (a). Surface response plots of the DU recovery
for each serotype based on formulations containing MSG and MgCl2 in combination with 10% sorbitol (without mannitol) (b).
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not shown). As such, formulations might be optimized for Tg’
by increasing the sorbitol-MSG content in order to be capable
to lyophilize at higher temperatures resulting in shorter pro-
cess time.
Table III Sorbitol (8–12% w/v),
MgCl2 (5–12% w/v) and MSG
(5–12% w/v) Tested in a Central
Composite Circumscribed
Design. DU Recoveries were
Determined per Serotype Directly
After Lyophilization and After
Accelerated Stability Testing
(one week at 45°C)
Sorbitol MgCl2 MSG DU recovery (%) DU recovery (%)
Directly after lyophilization Stability 45°C
T1 T2 T3 T1 T2 T3
O1 8% 5% 5% 98.6 96.5 85.7 91.9 97.0 55.2
O2 12% 5% 5% 88.9 88.7 65.2 87.6 91.6 73.7
O3 8% 12% 5% 76.0 82.4 33.6 62.5 49.2 12.2
O4 12% 12% 5% 89.4 91.7 59.1 95.8 90.8 48.2
O5 8% 5% 12% 90.6 81.9 70.7 86.0 81.4 57.5
O6 12% 5% 12% 79.3 82.5 62.1 80.2 77.0 39.4
O7 8% 12% 12% 84.9 86.7 64.6 92.0 84.6 63.5
O8 12% 12% 12% 87.9 82.5 73.0 90.3 86.7 69.8
O9 6.6% 8.5% 8.5% 90.0 99.3 84.8 93.3 90.6 73.0
O10 13.4% 8.5% 8.5% 86.2 85.3 67.4 86.1 85.3 69.3
O11 10% 2.6% 8.5% 77.5 72.4 47.4 74.4 60.7 29.9
O12 10% 14.4% 8.5% 89.1 84.6 63.6 91.7 72.7 40.0
O13 10% 8.5% 2.6% 98.1 85.2 49.2 93.0 83.3 42.2
O14 10% 8.5% 14.4% 84.7 70.3 66.3 74.8 81.2 35.5
O15 10% 8.5% 8.5% 86.6 88.4 68.2 90.1 91.1 67.3
O16 10% 8.5% 8.5% 92.2 90.8 75.1 93.5 89.1 69.2
O17 10% 8.5% 8.5% 96.0 98.3 76.7 91.7 94.0 57.0
Fig. 6 Contour plots show the
effect of MSG (5–12% w/v) and
MgCl2 (5–12%w/v) in combination
with 8% (a), 10% (b) or 12% w/v
sorbitol (c) on the DU recovery
after lyophilization and subsequent
accelerated stability testing for
serotype 3.
2626 Kraan, van Herpen, Kersten and Amorij
Again, it was observed that there are some divergences
between the serotypes regarding their preference for stabi-
lizers during lyophilization, whereas all serotypes seemed to
prefer the presence of MSG and MgCl2 during stability test-
ing. The surface response plots demonstrate that for type 1,
the highest DU recoveries after lyophilization were found in a
formulation containing 10% sorbitol in the presence of the
highest amounts of MSG, regardless the MgCl2 concentra-
tion, whereas both additives have no significant effect on type
2 (Fig. 5b). Though, type 3 showed to be most delicate for
small differences in excipient concentrations with maximal
DU recoveries of more than 80% with a formulation contain-
ing 10% sorbitol, 5–10% MgCl2 and 4–8% MSG.
Optimization
With the purpose to optimize the formulation, a response
surface methodology design was implemented. Hence, a cen-
tral composite circumscribed (CCC) (43) study set-up with the
factors sorbitol (8–12% w/v), MSG (8–12% w/v) and MgCl2
(5–10% w/v) was designed (Table III) and DU recovery was
determined directly after lyophilization. An extensive stability
study was included here as well to test whether the dried IPV
formulation has an improved stability when compared with
the conventional liquid IPV.
Within the design of the study, all formulations resulted in
comparable recoveries after lyophilization and subsequent stor-
age (Table III). This indicates the formulation robustness of the
formulation based on sorbitol (8–12%w/v),MSG (8–12%w/v)
and MgCl2 (5–10% w/v). Due to these small differences in DU
recovery after lyophilization and stability assessment between
the tested formulations, it was not possible to obtain a valid
model to describe the data. With all formulations, satisfying
stabilization was achieved for serotypes 1 and 2, which showed
recoveries of between 75% and 100% directly after lyophiliza-
tion and only a small loss (0% to maximal 15%) during accel-
erated stability testing (Table III). As mentioned above, type 3
showed to be the determining aspect in the decision for the final
concentrations of the three excipients in our IPV formulation.
Therefore, we decided to focus on the stability data of this
serotype. PLS regression describes the accelerated stability data
(1-week incubation at 45°C) well with high values for model
validity and reproducibility (respectively 0.67 and 0.86).
However, the predicting power of the model is limited (Q2=
0.43 instead of Q2>0.5). Despite this limitation, we requested
the contour plots (Fig. 6) to get an indication of the important
parameters to stabilize serotype 3. It seems that the best DU
recoveries (>70%) were obtained with the lowest sorbitol
(8% w/v) concentration in combination with the highest con-
centrations of bothMgCl2 andMSG (>10%w/v) or the highest
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Fig. 7 Stability testing of a
lyophilized trivalent IPV formulation
containing 10% (w/v) sorbitol,
8.5% (w/v) MgCl2 and 8.5% (w/v)
MSG at 25°C (a), 37°C (b) or up to
4 weeks at 45°C (c). The
freezedried formulation (FD IPV)
was compared with the
conventional liquid IPV (L IPV) and a
liquid IPV dialyzed against McIlvaine
buffer (L dIPV), which is the buffer
of choice during lyophilization.
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sorbitol (12% w/v) content combined with relatively low
amounts of MgCl2 and MSG (<8% w/v) (Fig. 6).
This experiment showed the robustness of the formulation
since many formulations containing sorbitol, MgCl2 and
MSG in the tested concentrations showed high recoveries
directly after lyophilization and preserved antigenicity during
accelerated stability. Based on excellent DU recoveries after
lyophilization and subsequent stability testing (Table III), the
formulation containing 10% (w/v) sorbitol, 8.5% (w/v)
MgCl2 and 8.5% (w/v) MSG was selected for additional
extensive stability testing up to 24 weeks at 25°C and 37°C,
and up to 1 month at 45°C. Both the conventional liquid IPV
and lyophilized IPV formulation remain stable during long-
term incubation at ambient temperature (Fig. 7a). However,
at elevated temperatures, the lyophilized IPV formula-
tion revealed its improved stability profile. Despite its
relatively high residual moisture content, which was de-
termined at 4.5±0.9%, minimal loss was observed for
the dried IPV after storage at temperatures above room
temperature where the liquid IPV has lost its antigenicity
completely (Fig. 7b and c).
This study shows the feasibility to convert IPV into the dry
state using lyophilization. The focus here was on development
and optimization of a dried IPV formulation. However, the
lyophilization process needs optimization as well, since the
RMC of our lyophilized IPV formulation exceeds the limit
of 3%water content from the European Pharmacopoeia. This
high residual water content is probably due to the presence of
MgCl2, a hexahydrate with strongly bound water, in the IPV
formulation. The duration of the secondary drying step
dictates the residual moisture level in a lyophilized
product (20), so probably prolongation of this drying
step and raising the end temperature of the lyophiliza-
tion process could decrease the RMC and thus could
possibly improve the final product.
CONCLUSION
The aim of the study was to develop a dried IPV
formulation with minimal loss during the drying process
and improved stability when compared with the conven-
tional liquid IPV, which could allow distribution and
storage under unfrigerated conditions. Extensive screen-
ing of a large number of excipients combined with a
DoE approach yielded a lyophilized IPV formulation
with remaining antigenicity for all serotypes when kept
at ambient or even higher temperatures.
Although further improvement and research is still
possible, this study showed the potential of a highly
stable and safe lyophilized polio vaccine, which could
be distributed in developing countries without the need
of a cold-chain transport.
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